NPs Basic Information

Name
Rutin
Molecular Formula C27H30O16
IUPAC Name*
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
SMILES
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O
InChI
InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1
InChIKey
IKGXIBQEEMLURG-NVPNHPEKSA-N
Synonyms
RUTIN; 153-18-4; rutoside; Quercetin 3-rutinoside; Birutan; Phytomelin; Myrticolorin; Eldrin; Globulariacitrin; Rutin trihydrate; Ilixanthin; Osyritrin; Paliuroside; Tanrutin; Sophorin; Bioflavonoid; Globularicitrin; Rutabion; Venoruton; 3-Rutinosyl quercetin; Violaquercitrin; Yunxianggan; 3-Rhamnoglucosylquercetin; Rutine; Rutozyd; Melin; Quercetin 3-O-rutinoside; Rutinic acid; Birutan Forte; Quercetin-3-rutinoside; Oxyritin; Rutinum; Rutosido; Rutosidum; Rutinion acid; Vitamin P; Quercitin 3-rutinoside; Novarrutina; Violaquercetrin; Birutin; Quercetin rhamnoglucosine; quercetin-3-O-rutinoside; Quercetin-3beta-rutinoside; Quercetin 3-rhamnoglucoside; Quercetol 3-rhamnoglucoside; C.I. 75730; Rutosid; Rutoside [INN]; 3,3',4',5,7-Pentahydroxyflavone-3-rutinoside; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; Quercetin 3-O-beta-D-rutinoside; 5G06TVY3R7; CHEMBL226335; CHEBI:28527; Rutoside (INN); 2-(3,4-DIHYDROXYPHENYL)-5,7-DIHYDROXY-4-OXO-4H-CHROMEN-3-YL 6-O-(6-DEOXY-ALPHA-L-MANNOPYRANOSYL)-BETA-D-GLUCOPYRANOSIDE; 3-[[6-O-(6-Deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one; 3-Rhamnoglucoside of 3,3',4',5,7-pentahydroxyflavone; NCGC00160628-01; NSC-9220; DSSTox_CID_2326; DSSTox_RID_76549; DSSTox_GSID_22326; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one; 4H-1-Benzopyran-4-one,3-[[6-O-(6-deoxy-a-L-mannopyranosyl)-b-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; RUT; Rutoside (rutin); 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4H-chromen-4-one; 3-((6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one; CAS-153-18-4; SMR000112560; Rutin [JAN:NF]; Rutosidum [INN-Latin]; Rutosido [INN-Spanish]; USAF CF-5; UNII-5G06TVY3R7; Neoisorutin; CCRIS 7564; Rutinoside, quercetin-3, beta-; hydroxyethylrutoside; Rutin (Rutoside); Venoruton (TN); 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-3-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-mannopyranoside; NSC 9220; EINECS 205-814-1; MFCD00006830; Rutin,(S); BRN 0075455; 3,3',4',5,7-Pentahydroxyflavone 3-rutinoside; AI3-19098; RUTIN [VANDF]; RUTIN [INCI]; 207671-50-9; RUTIN [DSC]; RUTIN [USP-RS]; RUTIN [MI]; Rutoside [INN:JAN:NF]; RUTOSIDE [WHO-DD]; beta-Quercetin-3-rutinoside; BIDD:PXR0020; SCHEMBL23243; 4H-1-Benzopyran-4-one, 3-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; 5-18-05-00519 (Beilstein Handbook Reference); MLS000759398; MLS001424098; BIDD:ER0377; DivK1c_000644; MEGxp0_000068; Rutin from Sophora japonica L.; DTXSID3022326; ACon1_000075; cid_5280805; HMS502A06; KBio1_000644; RUTIN (95%); NINDS_000644; 3,3',4',5,7-PENTAHYDROXYFLAVONE-3-RHAMNOGLUCOSIDE; HMS2051B06; 3'4'5,7-tetOH-Flavone-3-rut; Flavone, 3,3',4',5,7-pentahydroxy-, 3-(O-rhamnosylglucoside); HY-N0148; ZINC4096846; Quercetin 3-O-beta-delta-rutinoside; Tox21_111945; Tox21_202602; BDBM50217942; Glucopyranoside, quercetin-3 6-O-alpha-L-rhamnopyranosyl-, beta-D; Quercetin, 3-(6-O-alpha-L-rhamnopyranosyl-beta-D-glucopyranoside); s2350; 3,3',4',5,5',7-Hexahydroxyflavone (6-O-alpha-L-rhamnosyl-beta-D-glucoside); AKOS015895432; Glucopyranoside, quercetin-3 6-O-(6-deoxy-alpha-L-mannopyranosyl)-, beta-D-; Quercetin, 3-(6-0-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside); Tox21_111945_1; CCG-100999; CS-5573; DB01698; DS-9708; NC00249; IDI1_000644; Rutinoside, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl; NCGC00160628-02; NCGC00160628-03; NCGC00260150-01; 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; methyltetrahydro-2H-pyran-2-yloxy)methyl); 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3; R0035; C05625; D08499; AB00374708-09; tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one; A809400; EN300-18388402; Q407857; SR-01000759399; Q-201691; SR-01000759399-5; A8241DA0-6EC6-48BA-BD10-3F7BD61D42CE; BRD-K20482099-001-01-1; BRD-K20482099-001-11-0; 3,3,4,5,7-PENTAHYDROXYFLAVONE-3-RHAMNOGLUCOSIDE; 3-RHAMNOGLUCOSIDE OF 5,7,3',4'-TETRAHYDROXYFLAVONOL; quercetin 3-O-[alpha-L-rhamnosyl-(1->6)-beta-D-glucoside]; QUERCETIN 3-O-.ALPHA.-L-RHAMNOPYRANOSYL-.BETA.-D-GLUCOPYRANOSIDE; RUTIN (QUERCETIN-3-O-RUTINOSIDE) (CONSTITUENT OF GINKGO) [DSC]; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one;Rutin; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one; 2-(3,4-DIHYDROXYPHENYL)-5,7-DIHYDROXY-4H-CHROMEN-4-ONE-3-YL 6-O-.ALPHA.-L-RHAMNOPYRANOSYL-.BETA.-D-GLUCOSIDE; 4H-1-Benzopyran-4-one, 3-[[6-O-(6-deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]-oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-
CAS 153-18-4
PubChem CID 5280805
ChEMBL ID CHEMBL226335
*Note: the IUPAC Name was collected from PubChem.
Chemical Classification:
  • Kingdom: Organic compounds
    • Superclass: Phenylpropanoids and poly
      • Class: Flavonoids
        • Subclass: Flavonoid glycosides
          • Direct Parent: Flavonoid-3-O-glycosides

ClassyFire Version 1.0
PMID:27867422

NPs Species Source

Endophyte ID Endophyte Name Family Genus Taxonomy ID GenBank ID Closest GenBank ID Reference
Endophyte ID Endophyte Name Family Genus Taxonomy ID GenBank ID Closest GenBank ID Reference

NPs Content

*Note: The vaules in Content Percentage are calculated by dividing the content value by the maximum content value in NP Content.
**Note: The units with different NP content, due to their incomparable values, are separated into different tables.

NPs Biological Activity

Bioactivity Name Target ID Target Name Target Type Target Organism Target Organism ID Potency of Bioactivity Activity Type Value Unit Endophyte ID Endophyte Name
Bioactivity Name Target ID Target Name Target Type Target Organism Target Organism ID Potency of Bioactivity Activity Type Value Unit Endophyte ID Endophyte Name

NPs Physi-Chem Properties

Molecular Weight: 610.5 ALogp: -1.3
HBD: 10 HBA: 16
Rotatable Bonds: 6 Lipinski's rule of five: Rejected
Polar Surface Area: 266.0 Aromatic Rings: 5
Heavy Atoms: 43 QED Weighted: 0.148

NPs ADMET Properties*

ADMET: Absorption

Caco-2 Permeability: -6.47 MDCK Permeability: 0.00001920
Pgp-inhibitor: 0.005 Pgp-substrate: 0.997
Human Intestinal Absorption (HIA): 0.876 20% Bioavailability (F20%): 0.038
30% Bioavailability (F30%): 0.999

ADMET: Distribution

Blood-Brain-Barrier Penetration (BBB): 0.041 Plasma Protein Binding (PPB): 87.11%
Volume Distribution (VD): 0.701 Fu: 17.02%

ADMET: Metabolism

CYP1A2-inhibitor: 0.121 CYP1A2-substrate: 0.041
CYP2C19-inhibitor: 0.035 CYP2C19-substrate: 0.048
CYP2C9-inhibitor: 0.018 CYP2C9-substrate: 0.139
CYP2D6-inhibitor: 0.056 CYP2D6-substrate: 0.129
CYP3A4-inhibitor: 0.039 CYP3A4-substrate: 0.003

ADMET: Excretion

Clearance (CL): 1.502 Half-life (T1/2): 0.728

ADMET: Toxicity

hERG Blockers: 0.227 Human Hepatotoxicity (H-HT): 0.083
Drug-inuced Liver Injury (DILI): 0.982 AMES Toxicity: 0.851
Rat Oral Acute Toxicity: 0.053 Maximum Recommended Daily Dose: 0.01
Skin Sensitization: 0.929 Carcinogencity: 0.055
Eye Corrosion: 0.003 Eye Irritation: 0.609
Respiratory Toxicity: 0.025
*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.

Similar Compounds*

Compounds similar to EMNPD with top10 similarity:

Similar NPs Similar Drugs
NPs ID NPs 2D Structure Similarity Score TTD ID Drug 2D Structure Similarity Score
ENC001572 0.548 D0TC7C 0.595
ENC004734 0.533 D0I9HF 0.567
ENC001575 0.457 D0K8KX 0.451
ENC001529 0.451 D04AIT 0.378
ENC004475 0.420 D09LBS 0.360
ENC002201 0.392 D0Z2LG 0.360
ENC002582 0.386 D0A8RX 0.301
ENC001532 0.384 D0AZ8C 0.287
ENC002269 0.379 D0AD5C 0.284
ENC001534 0.378 D0P2IT 0.274
*Note: the compound similarity was calculated by RDKIT.